Recent Advancement in Car-T-Cell Therapy:

Vivek Pazhamalai Department of Bioengineering, Vels Institute of Science, Technology and Advanced Studies, Chennai, India G. Manideepa Department of Bioengineering, Vels Institute of Science, Technology and Advanced Studies, Chennai, India R. Mathumida Department of Bioengineering, Vels Institute of Science, Technology and Advanced Studies, Chennai, India Recent Advancement in Car-T-Cell Therapy

Chimeric antigen receptor is an emerging immunotherapy in the field of malignancy treatment. CAR-T cell therapy is the invitro modified t cells gain immunological properties that divert the defense system in our body to terminate the malignant cells. CARs are special receptors crafted to target a particular tumor antigen to functionally re-engineered T lymphocytes. Even though CARs can activate T cells similarly to endogenous T-cell receptors, minimal in vivo growth of CAR-T cells and unsatisfactory clinical outcomes have been a huge barrier to the medical application of this technique to date. The insertion of a costimulatory domain can improve T-cell responses mediated by chimeric antigen receptors even further. The commonly targeted hematological antigens are CD19 and BCMA, with mesothelin, GPC3, CEA, MUC1, HER2, and EGFR for solid malignancies. This chapter elaborates role and functions of CAR-T cell therapy in malignancy treatment, factors affecting efficacy, safety and future perspectives of CAR-T cell therapy.
chapter 9 2024 12 17 237 264 10.4018/979-8-3693-7728-4.ch009 20250211025826 https://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/979-8-3693-7728-4.ch009 https://www.igi-global.com/viewtitle.aspx?TitleId=366023 10.1038/mto.2016.14 10.15419/bmrat.v9i2.726 10.1158/2643-3230.BCD-21-0084 10.1016/j.adcanc.2022.100035 10.1155/2016/5474602 10.2217/fon-2021-1090 10.1080/21645515.2022.2114254 10.1080/21645515.2023.2210046 10.1084/jem.20230903 T cell exhaustion. A.Baessler 2024 42 Annual Review of Immunology BaesslerA.VignaliD. A. (2024). T cell exhaustion.Annual Review of Immunology, •••, 42.38166256 ••• 10.1093/neuonc/noy032 10.3390/cells13181596 10.1016/j.omto.2021.11.003 10.1038/bjp.2008.349 10.1093/oncolo/oyac163 Balancing the CAR T: Perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies. L. W.Buie 2021 27 The American Journal of Managed Care BuieL. W. (2021, August3). Balancing the CAR T: Perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies.The American Journal of Managed Care, •••, 27.34407360 ••• 10.1186/s13045-023-01504-7 10.1186/s12967-021-03193-7 10.1001/jamasurg.2017.3120 10.1126/science.288.5466.669 10.1177/2040620719841581 10.1016/j.intimp.2024.112112 10.1155/2019/5727516 10.3390/cancers15030663 10.1016/B978-0-323-46202-0.00029-7 10.3389/fimmu.2023.1113882 10.1016/j.drup.2020.100702 10.1016/j.omtm.2022.12.004 10.3389/fimmu.2018.03180 10.7554/eLife.75660 10.1016/j.biopha.2019.109685 10.1002/ajh.25418 10.1038/nrc.2016.97 10.4049/jimmunol.161.6.2791 10.3390/ijms241411803 10.3390/ijms241411803 10.1172/jci.insight.96976 10.1200/JCO.2022.40.16_suppl.8042 . Hansen, D. K., Sidana, S., Peres, L., Shune, L., Sborov, D. W., Hashmi, H., ... & Patel, K. K. (2022). Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. 10.1182/blood-2017-06-793141 10.1002/ajh.25445 10.1080/14712598.2021.1933939 10.54680/fr23310110112 10.1016/j.ebiom.2020.102931 10.1016/j.ebiom.2020.102931 10.1038/cddis.2015.162 10.1016/j.jtho.2017.10.001 10.1186/s12967-022-03442-3 10.1016/j.bbrc.2016.03.054 10.1016/j.bbmt.2018.12.758 10.1016/j.eng.2018.12.003 10.1080/14712598.2017.1322953 10.1001/jamaoncol.2019.3869 10.1007/s10549-020-06032-3 CAR T‐cell production using nonviral approaches. V.Lukjanov 2021 1 Journal of Immunology Research LukjanovV.KoutnáI.ŠimaraP. (2021). CAR T‐cell production using nonviral approaches.Journal of Immunology Research, 2021(1), 6644685.33855089 2021 10.1016/j.cryobiol.2017.08.008 10.1016/j.addr.2022.114301 10.1158/2159-8290.CD-18-0442 10.1016/j.blre.2022.100929 10.1186/s13287-020-02128-1 10.1111/imcb.12254 10.1080/14712598.2021.1889510 10.1182/blood-2009-09-242263 10.2174/1389201019666180418095526 10.3390/diseases10030060 10.3892/or.2019.7335 10.1056/NEJMoa2308917 10.1111/cas.14169 10.1038/mt.2011.131 10.1182/blood-2018-99-114152 . Nastoupil, L. J., Jain, M. D., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., ... & Locke, F. L. (2018). Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. 10.1038/mto.2016.6 10.1146/annurev-med-062315-120245 10.1016/j.omtm.2021.02.002 10.1016/j.jcyt.2022.05.003 10.1186/s13045-017-0437-8 10.1007/s00262-020-02735-0 10.1038/s41571-019-0297-y 10.1038/s41571-019-0297-y 10.1016/j.jcyt.2015.05.013 10.1111/ijlh.14121 10.1016/j.jcyt.2021.09.007 The role of chimeric antigen receptor-T cell therapy in the treatment of hematological malignancies: Advantages, trials, and tribulations, and the road ahead. S. R.Reddy 2021 2 Cureus ReddyS. R.LlukmaniA.HashimA.HaddadD. R.PatelD. S.AhmadF.GordonD. K. (2021). The role of chimeric antigen receptor-T cell therapy in the treatment of hematological malignancies: Advantages, trials, and tribulations, and the road ahead.Cureus, 13(2).33738156 13 10.2147/BLCTT.S327016 10.1080/10428194.2017.1387905 10.1158/2159-8290.CD-12-0548 10.1016/j.jcyt.2014.05.022 10.1056/NEJMoa1804980 10.1002/jha2.338 10.3390/biomedicines10081960 Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: Architecture and outcomes. N.Shirasu 2012 2377 6 Anticancer Research ShirasuN.KurokiM. (2012). Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: Architecture and outcomes.Anticancer Research, 32(6), 2377–2383.22641678 32 10.3389/fimmu.2020.01973 10.3389/fimmu.2022.947648 10.1016/S1470-2045(19)30823-X 10.1016/j.jtct.2023.07.012 10.1016/j.intimp.2024.111631 10.1038/nrd3463 10.3390/ijms20246223 10.2478/ahp-2020-0002 10.1016/j.cryobiol.2020.07.009 10.1155/2021/6616391 10.1126/sciadv.adn0881 10.1038/s41408-021-00469-5 10.1038/s41416-018-0325-1 10.3389/fimmu.2022.1034707 10.3389/fimmu.2022.1034707 10.2147/DDDT.S138765 10.1016/j.copbio.2018.01.025 10.1016/j.heliyon.2023.e21776 10.3389/fcell.2022.969020 10.1038/s41571-024-00881-3 10.1038/ni.2035 10.1111/imm.13642 10.1186/s13045-017-0444-9 10.1016/j.trecan.2022.04.004 10.3389/fimmu.2021.724211 10.1186/s40364-017-0081-z 10.1186/s12943-017-0753-1 10.7150/ijbs.14405 10.1038/s41598-022-14523-0 10.1016/j.apsb.2018.03.001 10.3390/cancers15133476 10.3390/biomedicines9010059